Diagonal Therapeutics raises $128m for antibodies discovery

2024-04-04

细胞疗法

Diagonal Therapeutics raises $128m for antibodies discovery

Preview

来源: Pharmaceutical Technology

Diagonal’s lead programme is being developed for the treatment of hereditary haemorrhagic telangiectasia. Credit: dimid_86 / Shutterstock.com.

Biotechnology company Diagonal Therapeutics has announced its launch, raising $128m through a Series A financing round for its new approach to discovering and developing agonist antibodies.

BVF Partners and Atlas Venture jointly led the financing round with participation from Checkpoint Capital, Frazier Life Sciences, Lightspeed Venture Partners, RA Capital Management, Velosity Capital and Viking Global Investors.

The company plans a new approach to develop antibodies to address the underlying causes of severely debilitating disease.

The funds will be utilised to advance its Diagonal platform and the development of a pipeline of new therapeutics.

The platform merges computational and experimental approaches to detect rare agonist antibodies that can re-activate deficient signalling pathways.

See Also:

Obsidian raises $160.5m to advance TIL cell therapy programme

Preview

来源: Pharmaceutical Technology

Harnessing pharmacovigilance to turn reactive investigation into active discovery

Preview

来源: Pharmaceutical Technology

Diagonal will also use the funds to progress its lead programme for hereditary haemorrhagic telangiectasia (HHT) through clinical proof-of-concept.

The asset activates a receptor complex in the TGF-β superfamily that is genetically impaired in HHT.

In preclinical models, agonist antibodies of Diagonal demonstrated the ability to hinder and reverse the formation of pathological vascular malformations associated with HHT.

The company also discovered antibody candidates against four complex targets, which could pave the way for new treatments for severe diseases such as pulmonary arterial hypertension.

Diagonal Therapeutics co-founder Alex Lugovskoy stated: “We are fundamentally changing how agonist antibody therapies are developed.

“The Diagonal platform allows us to overcome technical limitations that hindered agonist antibody discovery in the past, and we have demonstrated that we can efficiently advance novel drug candidates for diseases where patients have limited or no treatment options.

“Our approach enables us to treat a wide range of disorders where signalling pathways have been disrupted with agonist antibodies that have superior potency and selectivity, tunable and sustained pharmacology, excellent developability and low immunogenicity.”

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构

Diagonal Therapeutics, Inc.